Incanthera ltd
WebThe ICT has already successfully used this technology to improve the therapeutic index of a colchicine derivative (ICT2588, see Cancer Research, 2010, 70, 6902-6912), which is now licensed to University of Bradford spin-out company Incanthera Ltd (www.incanthera.com) and received global press coverage at the British Science Festival 2011 (e.g ... WebDeveloped by Prof Robert Falconer, Prof Paul Loadman and jointly funded by Cancer Research UK and Yorkshire Cancer Research the technology formed the basis for the launch of Incanthera Ltd (now plc), an ICT/University of Bradford spin-out company and now licenced to Ellipses Pharma.
Incanthera ltd
Did you know?
WebFeb 2, 2014 · Incanthera has raised a total of £650K in funding over 1 round. This was a Venture - Series Unknown round raised on Feb 2, 2014. Incanthera is funded by The North … WebFeb 28, 2024 · Developer Incanthera Class Antineoplastics; Colchicum alkaloids; Drug conjugates; Peptides Mechanism of Action Vascular disrupting agents Orphan Drug Status No New Molecular Entity Yes Highest Development Phases No development reported Breast cancer; Colorectal cancer; Lung cancer; Prostate cancer Most Recent Events
WebIncanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific WebIncanthera PLC is a UK-based, dermatology and oncology therapeutics company focusing on drug discovery and development of targeted medicines for the treatment of cancer. Deep …
Web'Incanthera Ltd Company Profile' is a complete analysis of the company's operations, strategies, outlook and historic performance. The research work analyzes key strategies … WebJun 12, 2024 · Incanthera Ltd Pre-IPO research – targeting the warheads 12 Jun 2024 / Corporate research By Dr Martin Hall, Dr Dorothea Hill, Dr Gregoire Pave. Download full report. Incanthera is a spin-out from the University of Bradford’s Institute of Cancer Therapeutics to exploit development opportunities being generated from this prestigious ...
WebIncanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies. View what we do SOL … Incanthera is a UK-based, dermatology and oncology therapeutics company focusing … The Company’s strategy of Acquire, Prepare, Commercialise is built on … Financial Calendar. December 07th , 2024 Half-yearly results for the six months … Latest from Incanthera. 2024; 2024; 2024; Archive March 13th, 2024 Director’s … Head Office: Incanthera Ltd 76 King Street Manchester M2 4NH, UK T: 0161 817 … The sustainability of Incanthera is evident in its mission statement: Transformative … The Company has created and continues to develop a rich pipeline of proprietary, … We are not currently recruiting at this time. If you would like to get in touch, please … Financial Calendar. December 07th , 2024 Half-yearly results for the six months …
WebPhone Number 441513315220. Incanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific matrix … greengates post officeWebMar 10, 2014 · North West oncology company Incanthera Ltd has acquired University of Salford drug discovery spin-out Onco-NX Ltd. The deal represents the first successful sale of a spin-out company from the University and will see both companies combine their expertise in targeted anticancer drugs, to develop a ground-breaking, therapeutics pipeline. flush read aloudWebFeb 28, 2024 · Incanthera Plc. The Company is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. … greengates primary school stocktonWebIncanthera Ltd is a Biotechnology, Pharmaceuticals, and Drug Discovery company located in Manchester, Manchester with $1.00 Million in revenue and 6 employees. Find top … greengates petrol stationWebSafe Harbor: The aforementioned statements and any future correspondence made by InCapta, Inc. (the Company) may be forward looking in nature, particularly related to the … flush reaktiongreengates primary stocktonWebIncanthera Ltd (Incanthera) is a biopharmaceutical company that discovers and develops therapeutic products for the treatment of cancer. The companys drug candidates under development include ICT2588, a vascular disrupting agent, based on the tumor-blasting technology; and ICT03 Es5, a targeted bioreductive agent; which are targeted at ... flush reaction